Soluble TNFR II/IgG1 Fc fusion protein treatment in the LPS-mediated septic shock of rats

Biomedicine and Pharmacotherapy

Volumn 63, Issue 7, 2009, Pages 537-542

  Guo, Zhuying ^a   Wang, Shiting ^a   Jiao, Qiang ^a   Xu, Manghua ^a   Xu, Zhimei ^a  

^a School of Medicine   (China)

Author keywords

Lipopolysaccharide; Septic shock; Soluble tumor necrosis factor alpha receptor IgG1 Fc fusion protein; Tumor necrosis factor alpha

Indexed keywords

LIPOPOLYSACCHARIDE; MESSENGER RNA; RECOMBINANT PROTEIN; SOLUBLE TUMOR NECROSIS FACTOR RECEPTOR 2 IMMUNOGLOBULIN G1 FC FRAGMENT FUSION PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE MONITORING; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG CYTOTOXICITY; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; HYPOTENSION; INHIBITION KINETICS; LIVER PARENCHYMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; RAT; SEPTIC SHOCK; SURVIVAL RATE;

ANIMALS; BLOOD PRESSURE; HUMANS; IMMUNOGLOBULIN G; IMMUNOLOGIC FACTORS; LIPOPOLYSACCHARIDES; LIVER; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, TUMOR NECROSIS FACTOR; RNA, MESSENGER; SHOCK, SEPTIC; SURVIVAL RATE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 68049095003     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopha.2008.08.012     Document Type: Article

References (19)

1. Cirioni O., Giacometti A., Ghiselli R., Bergnach C., Orlando F., Silvestri C., et al. LL-37 protects rats against lethal sepsis caused by Gram-negative bacteria. Antimicrob Agents Chemother 50 5 (2006) 1672-1679
2. Rivera C.A., Wheeler M.D., Enomoto N., and Thurman R.G. A choline-rich diet improves survival in a rat model of endotoxin shock. Am J Physiol Gastrointest Liver Physiol 275 4 (1998) G862-G867
3. Liu S., Gallo D.J., Green A.M., Williams D.L., Gong X., Shapiro R.A., et al. Role of toll-like receptors in changes in gene expression and NF-κB activation in mouse hepatocytes stimulated with lipopolysaccharide. Infect Immun 70 7 (2002) 3433-3442
4. Avunduk M.C., Avunduk A.M., Oztekin E., Baltaci A.K., Ozyazgan Y., and Mogolkoc R. Etanercept treatment in the endotoxin-induced uveitis of rats. Exp Eye Res 79 3 (2004) 357-365
5. Koizumi K., Poulaki V., Doehmen S., Welsandt G., Radetzky S., Lappas A., et al. Contribution of TNF-alpha to leukocyte adhesion, vascular leakage, and apoptotic cell death in endotoxin-induced uveitis in vivo. Invest Ophthalmol Vis Sci 44 5 (2003) 2184-2191
6. Kim D.H., Park Y.S., Jeon E.J., Yeo S.W., Chang K.H., and Lee S.K. Effects of tumor necrosis factor alpha antagonist, platelet activating factor antagonist, and nitric oxide synthase inhibitor on experimental otitis media with effusion. Ann Otol Rhinol Laryngol 115 8 (2006) 617-623
7. Pedoto A., Nandi J., Yang Z.J., Wang J., Bosco G., Oler A., et al. Beneficial effect of hyperbaric oxygen pretreatment on lipopolysaccharide-induced shock in rats. Clin Exp Pharmacol Physiol 30 7 (2003) 482-488
8. Tang X., Metzger D., Leeman S., and Amar S. LPS-induced TNF-alpha factor (LITAF)-deficient mice express reduced LPS-induced cytokine: evidence for LITAF-dependent LPS signaling pathways. Proc Natl Acad Sci U S A 103 37 (2006) 13777-13782
9. Cockfield S.M., Ramassar V., and Halloran P.F. Regulation of IFN-gamma and tumor necrosis factor-alpha expression in vivo. Effects of cycloheximide and cyclosporine in normal and lipopolysaccharide-treated mice. J Immunol 150 (1993) 342-352
10. d'Emmanuele di Villa Bianca R., Lippolis L., Autore G., Popolo A., Marzocco S., Sorrentino L., et al. Dexamethasone improves vascular hyporeactivity induced by LPS in vivo by modulating ATP-sensitive potassium channels activity. Br J Pharmacol 140 1 (2003) 91-96
11. De Rycke L., Vandooren B., Kruithof E., De Keyser F., Veys E.M., and Baeten D. Tumor necrosis factor alpha blockade treatment down-modulates the increased systemic and local expression of toll-like receptor 2 and toll-like receptor 4 in spondylarthropathy. Arthritis Rheum 52 7 (2005) 2146-2158
12. Hinojosa J., Gomollón F., García S., Bastida G., Cabriada J.L., Saro C., et al. Efficacy and safety of short-term adalimumab treatment in patients with active Crohn's disease who lost response or showed intolerance to infliximab: a prospective, open-label, multicentre trial. Aliment Pharmacol Ther 25 4 (2007) 409-418
13. Quartuccio L., De Re V., Fabris M., Marzotto A., Franzolini N., Gasparotto D., et al. Atypical lymphoproliferation progressing into B-cell lymphoma in rheumatoid arthritis treated with different biological agents: clinical course and molecular characterization. Haematologica 91 5 (2006) 691-694
14. Rutgeerts P., Sandborn W.J., Fedorak R.N., Rachmilewitz D., Tarabar D., Gibson P., et al. Onercept for moderate-to-severe Crohn's disease: a randomized, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol 4 7 (2006) 888-893
15. Gilbert Jr. T.D., Smith D., and Ollendorf D.A. Patterns of use, dosing, and economic impact of biologic agent use in patients with rheumatoid arthritis: a retrospective cohort study. BMC Musculoskelet Disord 5 1 (2004) 36
16. Doan Q.V., Chiou C.F., and Dubois R.W. Review of eight pharmacoeconomic studies of the value of biologic DMARDs (adalimumab, etanercept, and infliximab) in the management of rheumatoid arthritis. J Manag Care Pharm 12 7 (2006) 555-569
17. Grohmann U., Van Snick J., Campanile F., Silla S., Giampietri A., Vacca C., et al. IL-9 protects mice from Gram-negative bacterial shock: suppression of TNF-α, IL-12, and IFN-γ, and induction of IL-10. J Immunol 164 (2000) 4197-4203
18. Matsumoto H., Tamura S., Kamada Y., Kiso S., Fukushima J., Wada A., et al. Adiponectin deficiency exacerbates lipopolysaccharide/d-galactosamine-induced liver injury in mice. World J Gastroenterol 12 21 (2006) 3352-3358
19. Yin M., Wheeler M.D., Kono H., Bradford B.U., Gallucci R.M., Luster M.I., et al. Essential role of tumor necrosis factor alpha in alcohol-induced liver injury in mice. Gastroenterology 117 4 (1999) 942-952